TriAct Therapeutics

TriAct Therapeutics’ Novel TrxR1 Inhibitor Receives FDA Rare Pediatric Disease Designation for Treatment of Pediatric Diffuse High Grade Gliomas

TriAct Therapeutics, a private, late clinical-stage oncology therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation (RPDD) to its novel, proprietary TrxR1 inhibitor (iniparib), for the treatment of patients with... - September 28, 2022